Oh boy. This move refers to BPC-157, TB-500, Mots-C, KPV, epitalon, and semax. A document outlining the decision indicates that this seems to be the Health Secretary’s call, even though FDA scientists advised against it in July. This broadens access, but still requires a patient-specific prescription and adverse reporting.
[Link: Kennedy to Allow Broad Use of Unapproved Peptide Injections | https://www.nytimes.com/2026/10/28/health/peptides-kennedy-fda.html | nytimes.com]
Oh boy. This move refers to BPC-157, TB-500, Mots-C, KPV, epitalon, and semax. A document outlining the decision indicates that this seems to be the Health Secretary’s call, even though FDA scientists advised against it in July. This broadens access, but still requires a patient-specific prescription and adverse reporting.
This is the title for the native ad
This story is currently in the Upcoming News queue because it received more dislikes than likes. Vote thumbs up to help promote it back to the Published homepage!
Browse Upcoming Feed